data for >10/91 days. The 17 patients included in the analysis were 15 female, mean age: 62.9 years, disease duration: 18.6 years, HAQ: 1.86. Three patients reported constant flare for 91 days (constant flare group), 6 patients self-reported 1 flare with periods of non-flare (intermittent flare group) and 8 patients did not report being in a flare (daily life group)In the daily life group, patients' individual mean pain scores ranged from 0.2 to 5.8, whereas in the intermittent flare group patients' individual mean pain scores ranged from 2.5 to 7.0 and in the constant flare group patients' individual mean pain scores ranged from 2.4 to 9.3. Thus some individual patients reported lower mean pain in flare than other patients reported on non-flare days, this was also the case with the other self-reported measures (see Table 1 ). Further 5/6 patients in the intermittent flare group rated their symptoms as more severe on non-flare days than on days in flare. Thus patients may be using different criteria other than symptoms to decide whether they are in flare. Whilst many patients reported traditional inflammatory flare of symptoms, other patients may be reporting flare based on experiencing overall loss of control in their lives and thus defining their overall disease activity as more severe (in flare) despite individual symptoms being less severe. The term avalanche flare is proposed for this cascading effect of life. This idea was supported by the qualitative interview data. Conclusion: Definitions of flare vary within and between patients and may not be defined by symptom severity alone. Clinicians need to be aware that patients use flare to explain a range of experiences. Understanding the terminology is necessary to improve communication and inform treatment decisions. Disclosure statement: The author has declared no conflicts of interest.
BIOSIMILARS IN PERSPECTIVE I20. THE SCIENCE OF BIOSIMILARS
John Isaacs 1 1 Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK Monoclonal antibodies and soluble receptor molecules are complex glycoproteins. Because they are grown in living cells, rather than being chemically synthesized, they are known as biologic therapies. Their properties are determined by their tertiary and quaternary structure, which is in turn dependent upon their primary amino acid sequence but also on post-translational modifications and potentially their formulation and packaging. As the first biologic therapies in RA approach patent expiration, new opportunities and challenges arise with the advent of the so-called biosimilars. These copycat molecules should be cheaper than the reference products that they attempt to emulate. Nonetheless, in contrast to chemically synthesized small molecule drugs, biologic therapies cannot be precisely copied into generic molecules. Several steps in the manufacturing and production process of a biologic therapy impact on post-translational features, such as its glycosylation profile, and subtle changes in manufacturing can lead to biologically relevant changes in the end product. Additionally, some details of the manufacturing process of a reference biologic drug may comprise proprietary information which is not available to a biosimilar manufacturer. Consequently, differences between a biosimilar and the reference product are inevitable and mean that their precise effects in vivo could differ, with potential implications for safety and efficacy. Regulatory pathways have been developed to identify and avoid, as far as possible, relevant differences between biosimilar and reference product. However, a clear understanding of the clinical implications of using biosimilars is needed by the healthcare community, in order to optimize treatment selection and overall patient care. It will also be important to conduct long-term, registry-style studies of biosimilars, and to clearly distinguish this new type of treatment from the reference product. Disclosure statement: J.I. has served as a consultant for Hospira.
I21. THE COMMERCIAL MARKETPLACE
Peter Stenico 1 1 BU Biopharmaceuticals and Oncology Injectables, Sandoz, Holzkirchen, Germany
Biologics have revolutionized modern medicine by offering targeted therapies to address complex, disabling and life-threatening diseases. By 2018, 7 out of the top 10 medicines will be biologics. The growing demand for these medicines is increasingly straining healthcare budgets and contributes to limiting patient access to treatment and optimal care. Biosimilars are biologic medicines approved via stringent regulatory pathways. Approved biosimilars have been proved to offer comparable clinical benefit to their reference products, having followed a rigorous development and production process in accordance with EMA and FDA requirements. Being successful requires advanced expertise. In Europe several biosimilars have been approved by EMA across molecules and companies. At large there is acceptance in the respective clinical practice. Importantly biosimilars can potentially lead to five advancements in holistic patient care: increased patient access, improved drug utilization, fostering of genuine competition that leads to projected savings, sustained innovation and advanced medicinal applications. Disclosure statement: The author has declared no conflicts of interest. Biopharmaceuticals including the TNF-a inhibitors, tocilizumab, abatacept and rituximab have an established place in the management of rheumatological diseases. The first biosimilar medicines have been successfully introduced into clinical practice in recent years, including somatropin, filgrastim, and recombinant erythropoietin. In 2013, the first biosimilar mAb was granted marketing authorization in the EU namely, biosimilar infliximab. This presentation reviews the regulatory processes and requirements for authorization of biosimilar medicines,
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